Skip to main content
SpringerLink
Log in

Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Severe sepsis is a common cause of death in critically ill patients. Several mechanisms have been implicated in the development of organ dysfunction in patients with severe sepsis. Among these, activation of inflammation and coagula-tion, together with endothelial dysfunction, seem to be major contributors. Several anti-inflammatory agents have been tried for the treatment of sepsis, with limited success. Anticoagulant drugs have been shown to be of potential interest for the therapy of severe sepsis. Among these agents, a natural anticoagulant named activated protein C, which is manufactured as a recombinant human protein under the name of drotrecogin alfa (activated), has been a topic of intense interest. Drotrecogin alfa (activated) is an antithrombotic and profibinolytic agent that also possesses anti-inflammatory and antiapoptotic properties. Small trials have shown that drotrecogin alfa (activated) reduces the sepsis-induced alterations in endothelial and microcirculatory function.

In this review, the benefit-risk balance of drotrecogin alfa (activated) is assessed. The results of one phase II trial, two phase III trials (one including patients with high and low risk of death, the other restricted to patients with low risk of death) and several cohort studies have been published. The PROWESS (Recombinant human protein C Worldwide Evaluation in Severe Sepsis; phase III) trial showed that drotrecogin alfa (activated) is associated with a reduction in the risk of death in patients with severe sepsis, but this benefit seems to be greater in patients at high risk of death. Acute Physiology and Chronic Health Evaluation (APACHE) II scores and the number of failing organs have been proposed as means to identify patients with sepsis who are at a high risk of death, but these criteria may sometimes not make good indicators, especially as the APACHE II score has not been validated for this purpose.

Bleeding is more common in drotrecogin alfa (activated)-treated patients than in placebo recipients; however, many of the additional episodes of bleeding in drotrecogin alfa (activated) recipients are procedure related. Importantly, bleeding did not outweigh the benefits of drotrecogin alfa (activated), as there was an overall survival benefit, provided only patients at high risk of death from sepsis were treated with drotrecogin alfa (activated). The bleeding rate associated with drotrecogin alfa (activated) was slightly higher in cohort studies than in clinical trials, but this may be related to the higher severity of illness in these patients. Thus, in clinical practice, great caution should be taken in the selection of patients to be treated, and unnecessary invasive procedures should be avoided in order to preserve the survival benefit conferred by drotrecogin alfa (activated).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2

Similar content being viewed by others

References

  1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–10

    Article  PubMed  CAS  Google Scholar 

  2. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546–54

    Article  PubMed  Google Scholar 

  3. Dombrovskiy VY, Martin AA, Sunderram J, et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244–50

    Article  PubMed  Google Scholar 

  4. Dombrovskiy VY, Martin AA, Sunderram J, et al. Facing the challenge: decreasing case fatality rates in severe sepsis despite 1009 increasing hospitalizations. Crit Care Med 2005; 33: 2555–62

    Article  PubMed  Google Scholar 

  5. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006; 10: R42

    Article  PubMed  Google Scholar 

  6. Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30: 580–8

    Article  PubMed  CAS  Google Scholar 

  7. Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589–96

    Article  PubMed  Google Scholar 

  8. Bateman RM, Walley KR. Microvascular resuscitation as a therapeutic goal in severe sepsis. Crit Care 2005; 9 Suppl. 4: S27–32

    Article  PubMed  Google Scholar 

  9. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754–8

    Article  PubMed  CAS  Google Scholar 

  10. Vincent JL, Moreno J, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 2000; 22: 707–10

    Article  Google Scholar 

  11. Levy MM, Macias WL, Vincent JL, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005; 33: 2194–201

    Article  PubMed  Google Scholar 

  12. Gopal I, Bhonagiri S, Ronco C, et al. Out of hospital outcome and quality of life in survivors of combined acute multiple organ and renal failure treated with continuous venovenous hemofiltration/hemodiafiltration. Intensive Care Med 1997; 23: 766–72

    Article  PubMed  CAS  Google Scholar 

  13. Korkeila M, Ruokonen E, Takala J. Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care. Intensive Care Med 2000; 26: 1824–31

    Article  PubMed  CAS  Google Scholar 

  14. Singer M, De Santis V, Vitale D, et al. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364: 545–8

    Article  PubMed  Google Scholar 

  15. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207–14

    Article  PubMed  CAS  Google Scholar 

  16. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63–78

    Article  PubMed  CAS  Google Scholar 

  17. Matejovic M, Krouzecky A, Radej J, et al. Successful reversal of resistent hypodynamic septic shock with levosimendan. Acta Anaesthesiol Scand 2005; 49: 127–8

    Article  PubMed  CAS  Google Scholar 

  18. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003; 112: 460–7

    PubMed  CAS  Google Scholar 

  19. Bastarache JA, Ware LB, Bernard GR. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27: 365–76

    Article  PubMed  Google Scholar 

  20. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004; 114: 321–7

    Article  PubMed  CAS  Google Scholar 

  21. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 7: 23–38

    Article  PubMed  Google Scholar 

  22. Shorr AF, Bernard GR, Dhainaut JF, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10: R92

    Article  PubMed  Google Scholar 

  23. Yan SB, Helterbrand JD, Hartman DL, et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001; 120: 915–22

    Article  PubMed  CAS  Google Scholar 

  24. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816–23

    Article  PubMed  CAS  Google Scholar 

  25. Mesters RM, Helterbrand J, Utterback BG, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000; 28: 2209–16

    Article  PubMed  CAS  Google Scholar 

  26. Wang W, Zolty E, Falk S, et al. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 2006; 291: F1090–5

    Article  PubMed  CAS  Google Scholar 

  27. Liaw PC, Neuenschwander PF, Smirnov MD, et al. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000; 275: 5447–52

    Article  PubMed  CAS  Google Scholar 

  28. Spek CA, Koster T, Rosendaal FR, et al. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1995; 15: 214–8

    Article  PubMed  CAS  Google Scholar 

  29. Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007; 35: 12–7

    Article  PubMed  CAS  Google Scholar 

  30. Dhainaut JF, Yan SB, Cariou A, et al. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002; 30: S318–24

    Article  PubMed  CAS  Google Scholar 

  31. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5–11

    PubMed  CAS  Google Scholar 

  32. Brueckmann M, Hoffmann U, Dvortsak E, et al. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004; 53: 528–33

    Article  PubMed  CAS  Google Scholar 

  33. Bilbault P, Lavaux T, Launoy A, et al. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 2007; 35: 69–75

    Article  PubMed  CAS  Google Scholar 

  34. Mosnier LO, Griffin JH. Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci 2006; 11: 2381–99

    Article  PubMed  CAS  Google Scholar 

  35. Hoffmann JN, Vollmar B, Laschke MW, et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32: 1011–7

    Article  PubMed  Google Scholar 

  36. Iba T, Kidokoro A, Fukunaga M, et al. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33: 368–72

    Article  PubMed  CAS  Google Scholar 

  37. Lehmann C, Meissner K, Knock A, et al. Activated protein C improves intestinal microcirculation in experimental endotox-aemia in the rat. Crit Care 2006; 10: R157

    Article  PubMed  Google Scholar 

  38. Kirschenbaum LA, Lopez WC, Ohrum P, et al. Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock. Crit Care Med 2006; 34: 2207–12

    Article  PubMed  CAS  Google Scholar 

  39. De Backer D, Verdant C, Chierego M, et al. Effects of drotecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 2006; 34: 1918–24

    Article  PubMed  Google Scholar 

  40. De Backer D, Creteur J, Preiser JC, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166: 98–104

    Article  PubMed  Google Scholar 

  41. Trzeciak S, Dellinger RP, Parrillo JE, et al. Early microcirculatory perfusion derangements in patients with severe sepsis 1010 and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 2007; 49: 88–98

    Article  PubMed  Google Scholar 

  42. Sakr Y, Dubois MJ, De Backer D, et al. Persistant microvasculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004; 32: 1825–31

    Article  PubMed  Google Scholar 

  43. Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001; 104: 1171–5

    Article  PubMed  CAS  Google Scholar 

  44. Wiel E, Costecalde ME, Lebuffe G, et al. Activated protein C increases sensitivity to vasoconstriction in rabbit Escherichia coli endotoxin-induced shock. Crit Care 2006; 10: R47

    Article  PubMed  Google Scholar 

  45. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178–84

    Article  PubMed  CAS  Google Scholar 

  46. Zeng W, Matter WF, Yan SB, et al. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 2004; 32: S302–8

    Article  PubMed  CAS  Google Scholar 

  47. Monnet X, Lamia B, Anguel N, et al. Rapid and beneficial hemodynamic effects of Activated Protein C during septic shock. Intensive Care Med 2005; 31: 1573–6

    Article  PubMed  CAS  Google Scholar 

  48. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051–9

    Article  PubMed  CAS  Google Scholar 

  49. Bernard GR, Vincent J-L, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709

    Article  PubMed  CAS  Google Scholar 

  50. Dhainaut JF, Yan SB, Margolis BD, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642–53

    PubMed  CAS  Google Scholar 

  51. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31: 834–40

    Article  PubMed  CAS  Google Scholar 

  52. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699–713

    Article  PubMed  CAS  Google Scholar 

  53. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12–9

    Article  PubMed  CAS  Google Scholar 

  54. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2: 1924–33

    Article  PubMed  CAS  Google Scholar 

  55. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32: 2199–206

    Article  PubMed  CAS  Google Scholar 

  56. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266–77

    Article  PubMed  CAS  Google Scholar 

  57. Rivers E, Nguyen B, Havstadt S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–77

    Article  PubMed  CAS  Google Scholar 

  58. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Al-modovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742–51

    Article  PubMed  Google Scholar 

  59. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589–96

    Article  PubMed  Google Scholar 

  60. Vincent JL, O’Brien Jr J, Wheeler A, et al. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006; 10: R74

    Article  PubMed  Google Scholar 

  61. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332–41

    Article  PubMed  CAS  Google Scholar 

  62. Laterre PF, Abraham E, Janes JM, et al. ADDRESS (ADminis-tration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation. Crit Care Med 2007; 35: 1457–63

    Article  PubMed  CAS  Google Scholar 

  63. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369: 836–43

    Article  PubMed  CAS  Google Scholar 

  64. Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004; 113: 7–17

    Article  PubMed  Google Scholar 

  65. Friedrich JO, Adhikari NK, Meade MO. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Crit Care 2006; 10: 145

    Article  PubMed  Google Scholar 

  66. Bernard GR, Macias WL, Joyce DE, et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003; 7: 155–63

    Article  PubMed  Google Scholar 

  67. Vincent JL, Nadel S, Kutsogiannis DJ, et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit Care 2005; 9: R331–43

    Article  PubMed  Google Scholar 

  68. Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004; 32: 2207–18

    PubMed  Google Scholar 

  69. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31: 1–11

    Article  PubMed  Google Scholar 

  70. Bertolini G, Rossi C, Anghileri A, et al. Use of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 2007; 33: 426–34

    Article  PubMed  CAS  Google Scholar 

  71. Kanji S, Perreault MM, Chant C, et al. Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 2007; 33: 517–23

    Article  PubMed  CAS  Google Scholar 

  72. Eichacker PQ, Danner RL, Suffredini AF, et al. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 2005; 33: 2426–8

    Article  PubMed  Google Scholar 

  73. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007; 33: 396–9

    Article  PubMed  Google Scholar 

  74. Steg PG, Lopez-Sendon J, Lopez DS, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68–73

    Article  PubMed  Google Scholar 

  75. Decruyenaere J, De Backer D, Laterre PF, et al. 90-day follow-up of patients treated with drotecogin alpha activated (DAA) for severe sepsis: a Belgian open label study [abstract]. Crit Care Med 2005; 33: A10

    Article  Google Scholar 

Download references

Acknowledgements

No sources of funding were used in the preparation of this article. The author participated as co-investigator in the PROWESS, ADDRESS and ENHANCE trials that were sponsored by Eli Lilly (manufacturing drotrecogin alfa [activated]), has received grants for studies from Eli Lilly and has received honoraria for lectures from Eli Lilly. He is also member of the advisory board of lsAdvances in Sepsis’ and ‘About sepsis’, a journal and a website sponsored at least in part by Eli Lilly.

The author has received honorarium from Talecris Biotherapeutics (manufacturing antithrombin) for participation in a round table on antithrombin and has also received grants and material for studies not related to the topic of the present article from other companies.

Author information

Authors and Affiliations

  1. Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles (ULB) r]Route de Lennik, 808, Brussels, B-1070, Belgium

    Daniel De Backer

Authors
  1. Daniel De Backer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel De Backer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Backer, D. Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis. Drug-Safety 30, 995–1010 (2007). https://doi.org/10.2165/00002018-200730110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200730110-00002

Keywords

Search

Navigation